US Edition
Medicines Authority Recommends Authorisation of Further Alzheimer's Medication
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
In certain Alzheimer's patients, antibodies may somewhat delay the course of the disease. Soon, a second active substance could come onto the market.
It would be the second antibody active substance in the EU. The EU Commission is now deciding on the authorisation
Millions of people suffer from Alzheimer's disease. In some cases, antibodies can delay the course of the disease. A second active substance could soon be launched on the market in Germany.The European Medicines Agency (EMA) has cleared the way for another drug against Alzheimer's disease. Following a re-examination, an EU market authorisation for the antibody donanemab is recommended for the treatment of the disease in the early stages, the EMA…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
